PHBI (Pharmagreen Biotech) Buyback Yield %: 0.00 (As of Jul. 13, 2026)


What is Pharmagreen Biotech Buyback Yield %?

Pharmagreen Biotech PHBI Buyback Yield % is 0.00 as of Jul. 13, 2026.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Pharmagreen Biotech's current buyback yield was 0.00%.

Pharmagreen Biotech Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Pharmagreen Biotech's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmagreen Biotech Buyback Yield % Chart

Pharmagreen Biotech Annual Data
Trend Apr08 Apr09 Sep18 Sep19 Sep20 Sep21 Sep22
Buyback Yield %
Get a 7-Day Free Trial 0.00 0.00 -0.52 -2.56 -4.23

Pharmagreen Biotech Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PHBI vs DVLP, CSTF, BLMS: Buyback Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmagreen Biotech Buyback Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Pharmagreen Biotech's Buyback Yield % falls into.


Pharmagreen Biotech Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Pharmagreen Biotech's Buyback Yield for the fiscal year that ended in Sep. 2022 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.187) / 4.42261
=-4.23%

Pharmagreen Biotech's annualized Buyback Yield for the quarter that ended in Jun. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 0.81193175
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Pharmagreen Biotech (PHBI) has a Buyback Yield % of 0.00 as of Jul. 13, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pharmagreen Biotech and its competitors.
Is Pharmagreen Biotech's Buyback Yield % too high?
Pharmagreen Biotech's current Buyback Yield % is 0.00.
How does Pharmagreen Biotech's Buyback Yield % compare to DVLP and CSTF?
Pharmagreen Biotech's Buyback Yield % of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pharmagreen Biotech and its competitors. Pharmagreen Biotech's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmagreen Biotech stock overvalued right now?
Pharmagreen Biotech (PHBI) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Pharmagreen Biotech (PHBI), the current Buyback Yield % is 0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmagreen Biotech Business Description

Address 112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.